A meta-analysis published in 2016, including 1350 ESCC patients, found no association between clinical characteristics and PD-L1 expression, but there was a trend of worse prognosis in patients with higher PD-L1 expression (HR = 1.65; 95% CI = 0.95–2.85; p = 0.07) [12]. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.